湖南尔康制药股份有限公司 证券代码：300267 证券简称：尔康制药 公告编号：2025-006 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于 2025 年 4 月 22 日以现场会议和通讯表决相结合的方式召开。本次会议的通 知于 2025 年 4 月 11 日以书面、邮件形式通知了全体监事。本次会议应参与表决 的监事 3 名，实际参与表决的监事 3 名。本次会议的通知、召开以及参会监事人 数均符合相关法律、法规、规则及《公司章程》的有关规定。 经全体监事认真审议，形成如下决议： 一、审议通过了《2024 年度监事会工作报告》 《2024 年度监事会工作报告》的具体内容详见中国证监会选定信息披露网 站。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 本议案需提交公司 2024 年年度股东大会审议。 二、审议通过了《2024 年度财务决算报告》 《2024 年度财务决算报告》的具体内容详见中国证监会选定信息披露网站。 表决结果：同意票 3 ...

Financial Performance - The company achieved operating revenue of CNY 1,139.61 million and a net profit attributable to shareholders of CNY -373.37 million, primarily due to decreased sales volume and prices of pharmaceutical intermediates and composite excipients [3]. - The company's operating revenue for 2024 was ¥1,139,612,276.29, a decrease of 36.09% compared to ¥1,783,118,780.92 in 2023 [18]. - The net profit attributable to shareholders for 2024 was -¥373,371,435.91, representing a decline of 91.16% from -¥195,322,353.99 in 2023 [18]. - The net cash flow from operating activities increased by 12.31% to ¥166,691,706.92 in 2024, compared to ¥148,420,737.14 in 2023 [18]. - The total assets at the end of 2024 were ¥5,199,734,491.19, down 5.10% from ¥5,479,068,857.74 at the end of 2023 [18]. - The company reported a basic earnings per share of -¥0.1810 for 2024, a decrease of 91.13% from -¥0.0947 in 2023 [18]. - The company experienced a significant decline in net profit after deducting non-recurring gains and losses, with a figure of -¥368,820,598.49 for 2024, down 59.24% from -¥231,617,811.86 in 2023 [18]. - Total revenue for 2024 was ¥1,139,612,276.29, a decrease of 36.09% compared to ¥1,783,118,780.92 in 2023 [53]. - The pharmaceutical sector generated ¥1,107,309,520.33, accounting for 97.16% of total revenue, down 36.11% from ¥1,733,220,265.90 in 2023 [53]. - Direct sales contributed ¥1,095,605,767.52, representing 96.14% of total revenue, a decline of 37.85% from ¥1,762,856,454.62 in 2023 [54]. Market Trends - The pharmaceutical manufacturing industry in China reported a total revenue of CNY 2,529.85 billion, remaining stable year-on-year, with a total profit of CNY 342.07 billion, down 1.1% from the previous year [4]. - The lithium battery cathode material market in China saw a shipment volume of 3.35 million tons, representing a year-on-year growth of 35% [5]. - The total installed capacity of new energy vehicle power batteries in China increased by 41.5% year-on-year, with sales growing by 28.4% [5]. - In 2024, China's new energy vehicle sales reached 12.866 million units, a year-on-year increase of 35.5%, with a market share of 40.9% [29]. - The total installed capacity of power batteries for new energy vehicles in China grew by 41.5% year-on-year in 2024, while sales increased by 28.4% [29]. - The shipment volume of energy storage lithium batteries in China increased by 64% year-on-year in 2024 [31]. Company Strategy and Operations - The company plans to further integrate and optimize resource allocation to strengthen traditional businesses and enhance the development of new energy materials [5]. - The company is focusing on enhancing innovation capabilities and increasing R&D investment to adapt to the evolving pharmaceutical landscape [27]. - The company is focusing on the upstream layout of the lithium carbonate industry chain, particularly in lithium mining [36]. - The company is actively involved in the formulation and revision of pharmaceutical excipient standards in the Chinese Pharmacopoeia [35]. - The company is focusing on upstream lithium resource development, enhancing its competitive edge in the new energy materials sector [43]. - The company has implemented a "sales-driven production" model to optimize production planning and inventory management [39]. - The company is actively responding to rising raw material prices by increasing stockpiling and adjusting procurement strategies [40]. - The company is exploring new internet-based marketing and operational models to improve product visibility and market capacity [42]. - The company is enhancing comprehensive budget management to analyze past performance and future market trends, aiming for effective budget assessment and strict execution [93]. - The company is implementing lean cost reduction activities focusing on key areas such as procurement, production, sales, logistics, and management to lower production costs and management expenses [93]. Research and Development - The company has obtained 13 patents during the reporting period, including 2 invention patents and 11 utility model patents [44]. - The company has a strong commitment to research and development, aiming to innovate and improve product offerings [117]. - The company aims to obtain drug registration certificates for several new products, enhancing its product structure [66]. - The company is leveraging AI technology to enhance research and development in pharmaceutical excipients, aiming for a transition from "function provider" to "efficacy enabler" in the industry [92]. Environmental and Social Responsibility - The company invested a total of 11.24 million yuan in environmental protection and related taxes in 2024 [148]. - The company has established a wastewater treatment plant with a daily capacity of 900 tons, operating normally with no exceedances reported [148]. - The company has implemented a comprehensive environmental monitoring plan, with data uploaded monthly to the national pollution source monitoring system [148]. - The company donated pharmaceuticals valued at 4.063 million yuan to support health initiatives in July 2024 [151]. - The company emphasizes employee welfare by providing diverse cultural and recreational facilities, including gyms and sports courts [150]. Governance and Management - The company emphasizes the importance of independent directors, ensuring they fulfill their duties independently and protect the interests of all shareholders, particularly minority shareholders [104]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with relevant laws and regulations [105]. - The company maintains a complete and independent financial accounting system, with no shared bank accounts with controlling shareholders, ensuring financial independence [107]. - The company has a dedicated investor relations team that actively engages with investors through various communication channels, enhancing transparency and trust [105]. - The company has established an internal control system to mitigate operational risks and improve governance, emphasizing compliance and internal audit [137]. Shareholder Information - The total number of shares is 2,062,604,870, with 31.04% being restricted shares [187]. - The controlling shareholder is Shuai Fangwen, holding 41.38% of the shares, totaling 853,574,906 shares, with 640,181,179 shares under lock-up conditions [193]. - The top ten shareholders include individuals and entities with a combined holding of over 80% of the total shares, indicating a concentrated ownership structure [194]. - The company has not experienced any changes in its controlling shareholder during the reporting period [195]. - The company has not engaged in any repurchase transactions among the top ten shareholders during the reporting period [194].

Financial Performance - The company's revenue for Q1 2025 was ¥353,547,866.17, representing a 28.19% increase compared to ¥275,789,340.20 in the same period last year[4] - Net profit attributable to shareholders reached ¥28,112,585.22, a significant increase of 868.91% from ¥2,901,461.74 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥24,709,317.94, up 839.24% from a loss of ¥3,342,539.14 in the previous year[4] - The company's basic earnings per share rose to ¥0.0136, an increase of 871.43% compared to ¥0.0014 in the same period last year[4] - Total operating revenue for the current period reached ¥353,547,866.17, a significant increase of 28.1% compared to ¥275,789,340.20 in the previous period[19] - Net profit attributable to the parent company was ¥28,112,585.22, compared to ¥2,901,461.74 in the previous period, marking a substantial increase[20] - Operating profit for the current period was ¥26,228,298.64, up from ¥838,832.93 in the previous period, indicating strong operational performance[20] - The company reported a total comprehensive income of ¥12,391,421.98, compared to -¥34,221,597.97 in the previous period, showing a recovery in overall performance[20] - The basic and diluted earnings per share were both ¥0.0136, up from ¥0.0014 in the previous period, indicating improved profitability[20] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥4,148,506.90, a decline of 138.77% compared to ¥10,699,220.82 in the same period last year[4] - Cash and cash equivalents at the end of the period totaled ¥497,470,142.04, an increase from ¥469,743,222.10 at the end of the previous period[24] - The company's cash and cash equivalents decreased to RMB 686,061,848.21 from RMB 698,537,949.74[17] - The total assets at the end of the reporting period were ¥5,124,329,676.91, a decrease of 1.45% from ¥5,199,734,491.19 at the end of the previous year[4] - Total liabilities and equity amounted to ¥5,124,329,676.91, a decrease from ¥5,199,734,491.19 in the previous period[19] Investments and Expenses - The company's investment income increased by 715.04% to ¥266.11 from ¥32.65 in the previous year, mainly due to higher returns from financial product investments[11] - The cash flow from investing activities improved significantly, with a net inflow of ¥7,337.05 compared to a net outflow of -¥20,063.45 in the same period last year, marking a 136.57% increase[12] - The company experienced a 67.97% reduction in selling expenses, which decreased to ¥812.86 from ¥2,537.79 year-on-year, primarily due to lower promotional costs[10] - Research and development expenses increased to ¥9,935,801.85 from ¥8,851,765.51, reflecting the company's commitment to innovation[19] Accounts and Liabilities - The company reported a significant increase in accounts receivable, which rose by 36.51% to ¥14,085.59 from ¥10,318.19 year-on-year, attributed to increased sales revenue[9] - The company's accounts receivable increased to RMB 140,855,852.22 from RMB 103,181,869.28[17] - Total liabilities decreased to RMB 709,570,569.44 from RMB 797,540,680.70[18] - Short-term borrowings decreased to RMB 401,261,527.78 from RMB 488,198,472.23[18] - The total non-current assets decreased to RMB 3,447,614,260.36 from RMB 3,482,652,834.83[18] - The company's retained earnings increased to RMB 1,194,203,400.81 from RMB 1,166,090,815.59[18] Subsidiaries and New Ventures - The company established a wholly-owned subsidiary, Hunan Guanha Technology Co., Ltd., with a registered capital of RMB 10 million to focus on new productivity investments[15] - The company's subsidiary in Nigeria, Erkang Mining, achieved a new operating income of RMB 77.2749 million during the reporting period[15] Other Information - The first quarter report has not been audited[25] - The new accounting standards will be implemented starting in 2025[25]

湖南尔康制药股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300267 证券简称：尔康制药 公告编号：2025-005 湖南尔康制药股份有限公司（以下简称"公司"）第五届董事会第十三次会议 于 2025 年 4 月 22 日以现场会议和通讯表决相结合的方式召开。本次会议的通知 于 2025 年 4 月 11 日以书面、邮件形式通知了全体董事。本次会议应参与表决的 董事 7 名，实际参与表决的董事 7 名，本次会议的通知、召开以及参与人数均符 合相关法律、法规、规则及《公司章程》的有关规定。 与会董事审阅了总经理孙庆荣先生提交的《2024 年度总经理工作报告》，并 认真审议下列议案，形成如下决议： 一、审议通过了《2024 年度董事会工作报告》 公司独立董事王军文先生、蒋悟真先生、谭雪先生向董事会提交了《独立董 事 2024 年度述职报告》，独立董事将在公司 2024 年年度股东大会上进行述职。 董事会依据独立董事出具的《独立董事关于独立性自查情况的报告》，编写 了《董事会关于独立董事独立性情况的专项报 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-007 湖南尔康制药股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次利润分配预案：不派发现金红利，不送红股，不以资本公积金转增 股本； 2、本次利润分配预案将以《关于〈2024 年度利润分配方案〉的议案》提交 公司 2024 年年度股东大会审议。 一、审议程序 湖南尔康制药股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日召开第 五届董事会第十三次会议、第五届监事会第十二次会议，分别审议通过了《关于 〈2024 年度利润分配预案〉的议案》，公司 2024 年度不派发现金红利，不送红 股，不以资本公积金转增股本。本次利润分配预案将以《关于〈2024 年度利润分 配方案〉的议案》提交公司 2024 年年度股东大会审议。 根据《公司法》《公司章程》相关规定，根据公司 2024 年度实际盈利情况， 为保障公司日常生产经营及战略发展需求，维持稳健的财务状况，防范潜在风险， 更好地维护公司及全体股东的长远利益，公司拟定 ...

Financial Performance Expectations - The company expects a net loss for the fiscal year 2024, estimated between 290 million and 390 million CNY, compared to a loss of 195.32 million CNY in the same period of 2023[3] - The expected loss after deducting non-recurring items is projected to be between 296.45 million and 396.45 million CNY, compared to a loss of 231.62 million CNY in the previous year[3] - The company anticipates a decrease in non-recurring gains contributing approximately 6.45 million CNY to net profit, a reduction of 29.85 million CNY compared to the same period last year[6] Performance Decline Factors - The decline in performance is attributed to changes in market supply and demand for pharmaceutical intermediates and composite additives, leading to reduced sales volume and price declines[5] - The company has recognized an impairment provision of 259.85 million CNY for assets showing signs of impairment[6] Financial Reporting and Caution - The financial data in the earnings forecast has not been audited by a registered accountant, but there are no significant discrepancies with the auditing firm[4] - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[7] - The detailed financial data will be disclosed in the annual report for 2024[7]

证券代码：300267 证券简称：尔康制药 公告编号：2024-030 湖南尔康制药股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召集人：公司董事会 （1）出席会议的总体情况 参加会议的股东及股东授权代表共 392 名，代表股份 1,010,847,742 股,占公 司总股份的 49.0083％。 3、召开时间： 现场会议时间：2024 年 12 月 20 日（星期五）下午 14：30 网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 12 月 20 日上午 09:15-09:25、09:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年 12 月 20 日 9:15--15:00 期间的任意时间。 4、股权登记日：2024 年 12 月 13 日（星期五） 5、现场会议召 ...

湖南启元律师事务所 关于湖南尔康制药股份有限公司 2024年第一次临时股东大会的 法律意见书 二0二四年十二月 湖南启元律师事务所 关于湖南尔康制药股份有限公司 2024 年第一次临时股东大会的法律意见书 致：湖南尔康制药股份有限公司 湖南启元律师事务所接受湖南尔康制药股份有限公司（以下简称"公司"） 的委托，指派律师出席了公司 2024 年第一次临时股东大会（以下简称"本次股 东大会"），对会议进行现场律师见证，并出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》等法律、 法规和规范性文件以及《湖南尔康制药股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，出具本法律意见书。 本律师出具本法律意见书基于公司已作出如下承诺：所有提供给本律师的文 件的正本以及经本律师查验与正本保持一致的副本均为真实、完整、可靠。 为出具本法律意见书，我们依法审核了公司提供的下列资料： 1. 公 司 于 2024 年 11 月 29 日 发 布 在 深 圳 证 券 交 易 所 网 站 （http://www.s ...

证券代码：300267 证券简称：尔康制药 公告编号：2024-022 湖南尔康制药股份有限公司 第五届监事会第十一次会议决议公告 同意公司 2025 年度为子公司（含孙公司及控股子公司）申请银行综合授信 提供连带责任担保，担保金额合计不超过 150,000 万元，其中：全资子公司湖南 湘利来化工有限公司（以下简称"湘利来"）不超过 60,000 万元、全资子公司湖 南湘易康制药有限公司（以下简称"湘易康"）不超过 25,000 万元、全资子公司 湖南素尔康生物科技有限公司（以下简称"素尔康"）不超过 10,000 万元、全资 子公司湖南尔康（香港）有限公司（以下简称"香港尔康"）不超过 20,000 万元、 全资孙公司江苏素康生物科技有限公司（以下简称"素康生物"）不超过 10,000 万元、控股子公司西藏昌都光宇利民药业有限责任公司（以下简称"光宇利民"） 不超过 25,000 万元人民币，实际担保金额以最终与授信银行签署的担保合同为 准。 监事会认为：公司 2025 年度为湘利来、湘易康、素尔康、香港尔康、素康 生物、光宇利民申请银行授信提供担保，有利于扩大子公司业务规模，满足其 经营发展需要。公司为上 ...

2、额度及期限 湖南尔康制药股份有限公司 开展套期保值业务的可行性分析报告 一、开展套期保值业务的目的 为充分利用商品期货套期保值功能、合理规避主要原材料及产成品价格波 动风险，降低价格波动对生产经营的影响；为规避和防范人民币汇率大幅波动 对公司造成不良影响，提高公司应对汇率波动风险抵御能力，增强财务稳健性。 根据实际业务开展需要，公司（含子公司）拟在2025年度开展套期保值业务， 包括商品期货套期保值业务、外汇套期保值业务。 二、开展套期保值业务的基本情况 1、涉及业务品种 本次公司（含子公司）开展商品期货套期保值期货品种限于在场内市场交 易的与公司的生产经营有直接关系的期货品种；开展的外汇套期保值业务只限 于从事与公司经营所使用的主要结算货币相同的币种，主要外币币种为美元等 跟实际业务相关的币种，开展的外汇套期保值业务包括但不限于外汇期货、银 行远期购汇等相关产品业务。 公司（含子公司）开展商品期货套期保值业务占用的保证金最高额度不超 过5,000万元人民币（不含期货标的实物交割款项），开展的外汇套期保值业务 任一时点的交易金额不超过6,000万美元或等值外币金额，上述额度在2025年度 均可循环滚动使用 ...